Loading...
XLONIMM
Market cap6mUSD
Dec 24, Last price  
1.24GBP
1D
5.98%
1Q
-32.24%
Jan 2017
-97.62%
Name

ImmuPharma PLC

Chart & Performance

D1W1MN
XLON:IMM chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
21.13%
Rev. gr., 5y
-12.64%
Revenues
0k
0025,00063,00057,00022,055,00032,00017,00000184,81576,407164,784150,46281,28177,925126,667118,35000
Net income
-3m
L-23.26%
1,00015,000-2,483,000-3,083,0004,677,0008,103,000-1,978,000-3,355,000-3,844,034-3,689,346-2,871,480-3,897,497-5,324,016-6,223,201-7,206,549-6,123,590-6,859,927-8,173,905-3,807,431-2,921,795
CFO
-1m
L-41.87%
1,00027,000-879,000-3,632,000-2,573,00011,964,000-6,845,000-3,367,000-3,257,138-3,913,867-2,490,565-4,148,358-6,486,100-4,421,022-4,721,134-4,221,386-3,329,401-4,833,172-2,347,065-1,364,407
Dividend
Dec 14, 2021300 GBP/sh
Earnings
Jun 03, 2025

Profile

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
URL
https://www.immupharma.co.uk/
IPO date
Oct 28, 2003
Employees
14
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
118
-6.57%
Cost of revenue
3,220
2,987
4,662
Unusual Expense (Income)
NOPBT
(3,220)
(2,987)
(4,543)
NOPBT Margin
Operating Taxes
(497)
(649)
(767)
Tax Rate
NOPAT
(2,723)
(2,338)
(3,777)
Net income
(2,922)
-23.26%
(3,807)
-53.42%
(8,174)
19.15%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,481
2,351
3,550
BB yield
-24.49%
-42.18%
-21.42%
Debt
Debt current
111
700
Long-term debt
Deferred revenue
Other long-term liabilities
1,451
Net debt
(1,037)
(1,440)
(3,470)
Cash flow
Cash from operating activities
(1,364)
(2,347)
(4,833)
CAPEX
(106)
(51)
Cash from investing activities
189
(77)
(50)
Cash from financing activities
722
1,548
702
FCF
(2,014)
(2,481)
(2,885)
Balance
Cash
208
668
1,649
Long term investments
829
772
1,821
Excess cash
1,037
1,440
3,465
Stockholders' equity
(28,261)
(22,830)
(19,389)
Invested Capital
29,317
25,173
23,534
ROIC
ROCE
EV
Common stock shares outstanding
362,005
302,913
251,164
Price
0.02
-9.24%
0.02
-72.12%
0.07
-50.56%
Market cap
6,045
8.47%
5,574
-66.38%
16,577
-37.97%
EV
5,008
4,134
13,107
EBITDA
(3,183)
(2,869)
(4,429)
EV/EBITDA
Interest
2
1,456
2,355
Interest/NOPBT